Rare Disease Insurance Denied: How to Appeal

Approximately 30 million Americans live with a rare disease — defined as a condition affecting fewer than 200,000 people in the United States. Despite FDA's orphan drug program having approved over 900 orphan drugs since 1983, patients with rare diseases routinely face insurance denials for treatments that may be the only approved therapy for their condition. This guide covers how to appeal effectively when insurance denies a rare disease treatment.

Why Rare Disease Treatments Are Denied

"Experimental" or "investigational" labeling. Insurers sometimes label FDA-approved orphan drugs as experimental, particularly treatments that received accelerated approval or were approved based on smaller clinical trials — which is typical for rare diseases where large randomized controlled trials are impossible to conduct. This label is incorrect for FDA-approved drugs and can be challenged.

Lack of coverage policies. Because rare disease drugs are rarely anticipated in benefit design, insurers may not have an established coverage policy for a given orphan drug. When no policy exists, some payers default to denial. This is challengeable — the absence of a coverage policy doesn't mean a drug isn't covered.

"Off-label" use. Even when a drug is FDA-approved for a condition, some insurers deny coverage for specific presentations, ages, or uses covered by the FDA label but not anticipated in the payer's criteria. Note that FDA-approved uses are not "off-label" — off-label refers to uses beyond the FDA-approved indication.

High cost and step therapy. Ultra-expensive rare disease drugs may face step therapy requirements, clinical criteria, or center-of-excellence requirements designed to control costs.

Diagnosis not confirmed to insurer's standards. Some payers require specific genetic testing, biomarker confirmation, or specialist documentation before approving rare disease therapies.

Key Appeal Arguments for Rare Disease Denials

The FDA Orphan Drug Designation Argument

If a drug carries FDA orphan drug designation and FDA approval for the patient's condition, it is definitively not experimental. FDA approval — including approval via the accelerated approval pathway (based on surrogate endpoints predictive of clinical benefit) — constitutes sufficient evidence of safety and efficacy for coverage purposes.

In your appeal, state explicitly: "This drug holds FDA approval (including the specific date and indication) under the Orphan Drug Act. Categorizing an FDA-approved drug as experimental is inconsistent with established law and clinical practice."

The "Only Available Treatment" Argument

For many rare diseases, the orphan drug is the only FDA-approved treatment. Denying it leaves the patient with no covered alternative — not "step therapy" to a different drug, but simply no treatment. This is a compelling and legally significant argument. State in your appeal: "There is no FDA-approved alternative therapy for [condition]. Denial of this medication leaves the patient without any covered treatment option for a serious, progressive, or life-threatening condition."

NORD and Disease-Specific Organization Support

The National Organization for Rare Disorders (NORD) and disease-specific patient advocacy organizations often have experience with specific insurance denials and can:

• Provide letters of support for appeals
• Connect patients with others who have successfully appealed similar denials
• Refer patients to attorneys who specialize in rare disease insurance cases
• Provide access to patient assistance programs

Engage NORD early in the appeal process.

State External Independent Review: Complete Guide" class="auto-link">External Review

All ACA-compliant health plans must provide access to external independent review after internal appeals are denied. For rare diseases, an external reviewer who is a specialist in the relevant field (e.g., metabolic diseases, hematology, neurology) may be designated. If the assigned reviewer lacks expertise in your rare disease, you can request that someone with appropriate expertise be assigned — this is particularly important for ultra-rare conditions.

State external review laws add an additional layer: many states have robust external review protections that go beyond federal requirements.

Compassionate Use and Expanded Access

If a drug isn't yet FDA-approved for your specific condition but is in clinical trials or available under expanded access, document this and argue for coverage on medical necessity grounds. The FDA's expanded access (compassionate use) program allows patients with serious conditions access to investigational treatments outside clinical trials when no comparable alternative is available.

Genetic Testing and Diagnosis Documentation

Submit complete genetic testing results, specialist clinical notes, and any biomarker confirmation required by the insurer. For rare diseases with clinical heterogeneity, include a detailed letter from a specialist in the rare disease explaining how the patient's presentation fits the diagnosis and why the prescribed treatment is appropriate.

Practical Steps for Rare Disease Appeals

1. Get a specialist involved. A physician specializing in your rare disease — ideally at an academic medical center or designated Center of Excellence — carries significant weight in appeals.
2. Request a peer-to-peer review. Ask the insurer to connect the specialist with their medical director for a direct clinical conversation.
3. Engage disease-specific patient advocacy organizations. Many have insurance case managers who have navigated these exact denials before.
4. Contact the manufacturer. Most orphan drug manufacturers have dedicated patient access teams with extensive experience in insurance appeals and typically provide free drug during the appeals process.
5. Pursue state external review. If internal appeals fail, escalate immediately to external review, requesting a reviewer with expertise in your condition.

Resources

• National Organization for Rare Disorders (NORD) (rarediseases.org) — patient assistance, advocacy, disease-specific organization directory
• Global Genes (globalgenes.org) — rare disease community and advocacy resources
• EveryLife Foundation for Rare Diseases — policy and insurance access advocacy
• Manufacturer patient assistance programs — virtually all rare disease drug manufacturers have patient access teams; contact the manufacturer directly

A rare disease denial is not the last word — FDA approval, the "only available treatment" argument, and external review rights make rare disease appeals among the most winnable categories.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?